Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Prime Medicine (Nasdaq: PRME) has successfully completed its public offering of 43.7 million shares of common stock at $3.30 per share, including the full exercise of the underwriters' option for 5.7 million additional shares. The biotechnology company, focused on developing curative genetic therapies, raised approximately $144.2 million in gross proceeds before deducting expenses.
The offering included a notable sale of 1,818,181 shares to the Cystic Fibrosis Foundation, for which underwriters received no commissions. TD Cowen and BMO Capital Markets served as joint book-running managers for the offering, which was conducted under Prime Medicine's previously filed shelf registration statement.
Prime Medicine (Nasdaq: PRME) ha completato con successo la sua offerta pubblica di 43,7 milioni di azioni ordinarie a 3,30 dollari per azione, includendo l'esercizio completo dell'opzione degli underwriter per ulteriori 5,7 milioni di azioni. L'azienda biotecnologica, specializzata nello sviluppo di terapie genetiche curative, ha raccolto circa 144,2 milioni di dollari di proventi lordi prima delle spese.
L'offerta ha incluso una vendita significativa di 1.818.181 azioni alla Cystic Fibrosis Foundation, per la quale gli underwriter non hanno ricevuto commissioni. TD Cowen e BMO Capital Markets hanno agito come gestori congiunti dell'offerta, condotta sotto la dichiarazione di registrazione a scaglioni precedentemente depositata da Prime Medicine.
Prime Medicine (Nasdaq: PRME) ha completado con éxito su oferta pública de 43,7 millones de acciones ordinarias a 3,30 dólares por acción, incluyendo el ejercicio total de la opción de los suscriptores para 5,7 millones de acciones adicionales. La compañía biotecnológica, enfocada en desarrollar terapias genéticas curativas, recaudó aproximadamente 144,2 millones de dólares en ingresos brutos antes de deducir gastos.
La oferta incluyó una venta destacada de 1.818.181 acciones a la Cystic Fibrosis Foundation, para la cual los suscriptores no recibieron comisiones. TD Cowen y BMO Capital Markets actuaron como gestores conjuntos del libro de la oferta, que se realizó bajo la declaración de registro previa presentada por Prime Medicine.
Prime Medicine (나스닥: PRME)는 4,370만 주의 보통주를 주당 3.30달러에 성공적으로 공개 발행했으며, 인수인 옵션 570만 주를 전액 행사했습니다. 유전 치료제 개발에 주력하는 이 생명공학 회사는 비용 공제 전 약 1억 4,420만 달러의 총 수익을 조달했습니다.
이번 공모에는 인수인들이 수수료를 받지 않은 1,818,181주를 낭포성 섬유증 재단(Cystic Fibrosis Foundation)에 판매하는 중요한 거래가 포함되었습니다. TD Cowen과 BMO Capital Markets가 공동 주관사로 참여했으며, 이번 공모는 Prime Medicine이 이전에 제출한 선등록 명세서에 따라 진행되었습니다.
Prime Medicine (Nasdaq : PRME) a réussi son offre publique de 43,7 millions d’actions ordinaires à 3,30 dollars par action, incluant l’exercice complet de l’option des souscripteurs pour 5,7 millions d’actions supplémentaires. La société biotechnologique, spécialisée dans le développement de thérapies génétiques curatives, a levé environ 144,2 millions de dollars de produits bruts avant déduction des frais.
L’offre comprenait une vente notable de 1 818 181 actions à la Cystic Fibrosis Foundation, pour laquelle les souscripteurs n’ont perçu aucune commission. TD Cowen et BMO Capital Markets ont agi en tant que gestionnaires conjoints de l’offre, réalisée sous la déclaration d’enregistrement préalable déposée par Prime Medicine.
Prime Medicine (Nasdaq: PRME) hat erfolgreich eine öffentliche Platzierung von 43,7 Millionen Stammaktien zu je 3,30 US-Dollar abgeschlossen, einschließlich der vollständigen Ausübung der Option der Underwriter für zusätzliche 5,7 Millionen Aktien. Das Biotechnologieunternehmen, das sich auf die Entwicklung heilender Gentherapien spezialisiert hat, erzielte vor Abzug der Kosten einen Bruttoerlös von etwa 144,2 Millionen US-Dollar.
Das Angebot beinhaltete einen bemerkenswerten Verkauf von 1.818.181 Aktien an die Cystic Fibrosis Foundation, für die die Underwriter keine Provisionen erhielten. TD Cowen und BMO Capital Markets fungierten als gemeinsame Bookrunner für das Angebot, das unter der zuvor eingereichten Shelf-Registrierung von Prime Medicine durchgeführt wurde.
- Raised significant capital of $144.2 million in gross proceeds
- Full exercise of underwriters' option indicates strong demand
- Strategic investment from Cystic Fibrosis Foundation demonstrates institutional confidence
- Significant dilution for existing shareholders with 43.7 million new shares
- Relatively low offering price of $3.30 per share
Insights
Prime Medicine secured $144.2M through public offering, strengthening its financial position for advancing its gene therapy pipeline.
Prime Medicine has successfully completed a significant capital raise through a public offering of 43.7 million shares at $3.30 per share, generating
This capital infusion substantially strengthens Prime Medicine's balance sheet, providing crucial runway to advance its pipeline of prime editing genetic therapies. The offering price of $3.30 per share suggests the company is operating in a challenging biotech funding environment, but the successful completion demonstrates investor confidence in Prime Medicine's scientific approach despite market conditions.
For a clinical-stage biotech company developing novel gene therapies, securing this level of funding is strategically important as the development pathway for genetic medicines typically requires substantial capital. The involvement of the Cystic Fibrosis Foundation as a strategic investor also suggests potential future collaboration opportunities in developing treatments for CF, which could accelerate the company's pathway to addressing this specific indication.
Prime Medicine can now operate from a position of enhanced financial stability as it works to translate its prime editing platform technology into potential one-time curative genetic therapies across multiple disease areas.
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of
TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering.
The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
FAQ
How much money did Prime Medicine (PRME) raise in its August 2025 public offering?
What was the Cystic Fibrosis Foundation's involvement in Prime Medicine's 2025 offering?
Who were the underwriters for Prime Medicine's August 2025 public offering?
How many additional shares were included through the underwriters' option in PRME's offering?
What was the price per share for Prime Medicine's 2025 public offering?
